RxDoctor Payments DataLook up a doctor →

Mayda Melendez, MD

Family Medicine · Wilmington, DENPI 1760491807

Payments from drug & device makers

$11,995in general payments, 2019–2025

Across 613 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Lilly USA, LLC$978
  • Boehringer Ingelheim$797
  • Pfizer$788
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$11,73398%
  • Education$2622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,995 in reported general payments places this provider in the 90th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$2,467,246
Medicare patients
533
Services billed
54,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide43$44,805
JardianceEmpagliflozin24$39,552
Synjardy XrEmpagliflozin/Metformin Hcl20$29,458
OzempicSemaglutide14$27,470
TrulicityDulaglutide14$22,688
Trijardy XrEmpaglifloz/Linaglip/Metformin12$17,416
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$15,274
FarxigaDapagliflozin Propanediol20$14,374
Aimovig AutoinjectorErenumab-Aooe17$11,985
Arnuity ElliptaFluticasone Furoate17$3,436
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro14$2,327
Fluticasone Propionate41$1,965
Omeprazole94$1,733
Albuterol Sulfate HfaAlbuterol Sulfate43$1,685
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen66$1,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr$797$86,42756 claims
Lilly USA, LLCMounjaro, Trulicity$978$67,49357 claims
AstraZenecaBreztri Aerosphere, Farxiga$2,859$29,64934 claims
Novo NordiskOzempic$1,260$27,47014 claims
GSKArnuity Ellipta$163$3,43617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 family medicine providers in Delaware.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →